Renaissance Technologies LLC Has $2.60 Million Position in AC Immune SA (NASDAQ:ACIU)

Renaissance Technologies LLC raised its stake in AC Immune SA (NASDAQ:ACIU) by 26.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 652,079 shares of the company’s stock after buying an additional 136,300 shares during the quarter. Renaissance Technologies LLC owned 0.66% of AC Immune worth $2,602,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ACIU. Vanguard Capital Wealth Advisors purchased a new position in shares of AC Immune during the 2nd quarter valued at $56,000. Assenagon Asset Management S.A. grew its stake in AC Immune by 294.7% in the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after purchasing an additional 328,312 shares in the last quarter. Silverberg Bernstein Capital Management LLC purchased a new position in AC Immune in the second quarter valued at about $40,000. Redmile Group LLC increased its position in AC Immune by 0.4% in the 1st quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock worth $5,941,000 after purchasing an additional 7,031 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in shares of AC Immune during the 1st quarter worth about $30,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research note on Wednesday, September 18th. StockNews.com cut shares of AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday.

AC Immune Price Performance

NASDAQ ACIU opened at $3.75 on Wednesday. AC Immune SA has a fifty-two week low of $2.20 and a fifty-two week high of $5.14. The stock’s 50-day moving average is $3.44 and its two-hundred day moving average is $3.39. The firm has a market cap of $370.87 million, a P/E ratio of -5.43 and a beta of 1.24.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $91.60 million. On average, equities analysts expect that AC Immune SA will post -0.89 EPS for the current year.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.